Monument Capital Management Buys 6,812 Shares of Merck & Co., Inc. $MRK

Monument Capital Management grew its position in shares of Merck & Co., Inc. (NYSE:MRK) by 57.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,690 shares of the company’s stock after purchasing an additional 6,812 shares during the period. Monument Capital Management’s holdings in Merck & Co., Inc. were worth $1,967,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in MRK. Brighton Jones LLC boosted its position in shares of Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after purchasing an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC increased its position in Merck & Co., Inc. by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after purchasing an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC increased its position in Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after purchasing an additional 359,356 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MRK has been the subject of a number of analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Monday, March 30th. UBS Group upped their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Cantor Fitzgerald lifted their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $128.47.

Merck & Co., Inc. Stock Down 0.2%

NYSE:MRK opened at $119.94 on Wednesday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The company has a market cap of $296.24 billion, a price-to-earnings ratio of 16.48, a price-to-earnings-growth ratio of 2.42 and a beta of 0.26. The stock has a fifty day simple moving average of $119.27 and a 200-day simple moving average of $105.42. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 37,685 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares of the company’s stock, valued at $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the transaction, the chief marketing officer owned 80,615 shares in the company, valued at $9,825,356.20. The trade was a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is owned by corporate insiders.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted Priority Review to Merck and Daiichi Sankyo’s BLA for ifinatamab deruxtecan for previously treated extensive‑stage small cell lung cancer — if approved this could be a first‑in‑class B7‑H3 antibody‑drug conjugate with meaningful upside to oncology revenue. Article
• Positive Sentiment: UBS raised its price target on MRK from $130 to $145 and maintained a Buy rating, signaling analyst confidence in Merck’s growth trajectory and providing a potential catalyst for upside. Article
• Neutral Sentiment: Industry context — large pharma shifting to smaller, disciplined deals may leave room for strategic partnerships and targeted M&A that could benefit Merck or its competitors, but no direct near‑term impact is specified. Article
• Neutral Sentiment: Sector moves: positive clinical readouts at peers (e.g., Revolution Medicines) are lifting biotech sentiment broadly — this can shift investor flows within healthcare but does not directly change Merck’s fundamentals. Article
• Neutral Sentiment: Investor commentary pieces highlight profitability as an important factor for long‑term holders; Merck’s margins and guidance remain points investors watch but are not new catalysts. Article
• Negative Sentiment: Reputational and policy risk: reporting on how Merck built a broad patent “wall” around Keytruda and the high U.S. costs underscores political, regulatory and payer scrutiny that could pressure pricing and future revenue. Article
• Negative Sentiment: Near‑term selling pressure noted in recent market reports — short‑term stock weakness has appeared even as company news flows positive, suggesting traders are balancing the FDA news with broader market and sector dynamics. Article

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.